Salvinorin A
Viewing r1.a1 — Oct 2, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Salvinorin A (divinorin A) is a dissociative of the neoclerodane diterpene class. It is the principal psychoactive compound in Salvia divinorum and the most potent naturally occurring hallucinogen identified to date.[1] It activates kappa-opioid receptors in the brain — not serotonin receptors — producing a profound and unusual dissociative state.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Isolated from Salvia divinorum in 1982, the compound's pharmacological target was unknown for two decades.[3] In 2002, Bryan Roth identified it as a selective kappa-opioid agonist — the first naturally occurring non-nitrogenous compound to work through opioid pathways, overturning the assumption that plant hallucinogens must act on serotonin.[2] It remains unscheduled at the federal level in the United States, though approximately 27 states and many countries have restricted it.
Subjective effects include intense dissociation, loss of body ownership, vivid internal imagery, ego dissolution, and amnesia.[1] The experience is defined by an abrupt, involuntary departure from ordinary reality — more commonly described as bewildering and dysphoric than expansive, setting it sharply apart from serotonergic psychedelics.[1] Confusion, profound dysphoria, and complete disconnection from the outside world are characteristic unwanted effects.[4]
Salvinorin A produces no physical dependence — its aversive character and suppression of reward-circuit dopamine make compulsive use self-limiting.[5] The primary risks are psychological: onset is near-instantaneous, and high doses produce complete incapacitation with acute danger from falls and burns.[6] The evidence base is sparse — three controlled human studies exist, and no lethal dose has been established in any species.[5]
History[edit]
History
Discovery
Salvinorin A was first isolated and structurally characterized in 1982 by Alfredo Ortega, Anthony Blount, and Peter Manchand, who confirmed by X-ray crystallography that it was a terpenoid, not an alkaloid.[7] Two years later, Leander Valdés III independently isolated the same compound and named it divinorin A.[8] Ortega's earlier publication established priority, and the name salvinorin A prevailed.
Scientific significance
The compound's receptor target remained unknown for twenty years. In 2002, Bryan Roth identified it as a selective κ-opioid agonist with no activity at serotonin receptors or 50 other molecular targets.[2] This opened the door to controlled human studies between 2012 and 2016,[9][4][1] and in 2020 the first human brain imaging study mapped its effects on network connectivity.[10]
Modern status
No clinical trials are recruiting as of May 2026. Early-stage preclinical research is exploring possible neuroprotective and anti-inflammatory uses. In 2023, researchers resolved the atomic structure of the kappa-opioid receptor bound to salvinorin compounds, opening new possibilities for drug design.[11]
The name salvinorin derives from the genus Salvia (Latin salvare, "to save"), while divinorin — Valdés's independent name — references Salvia divinorum ("sage of the diviners").[8] The Mazatec names ska María Pastora and hojas de la Pastora associate the plant with the Virgin Mary as spiritual intercessor.[3]
Salvia divinorum has been used by the Mazatec people of Oaxaca in healing and divination ceremonies for centuries.[3][13] José Luis Díaz documented traditional water preparations between 1973 and 1983, finding effects qualitatively milder than smoked use — light-headedness, body sensation distortion, and amplified imagery rather than overwhelming dissociation.[13]
Chemistry[edit]
Chemistry
Structural class
Salvinorin A is a neoclerodane diterpene — a terpenoid, not an alkaloid.[7][2][3] Every other known plant hallucinogen contains nitrogen; salvinorin A does not. Its molecular formula is C₂₃H₂₈O₈ (molecular weight 432.5 g/mol). It is a white crystalline powder, poorly soluble in water and soluble in ethanol.[14]
Natural occurrence
Salvia divinorum produces a family of related diterpenes — salvinorins B through I — but only salvinorin A has the intact C-2 acetate ester required for high-affinity receptor binding.[15][16] When metabolic enzymes remove that group, the resulting compound (salvinorin B) is inactive.[15] This structural specificity has made salvinorin A a starting point for designing new κ-opioid drugs.[17]
Pharmacology[edit]
Pharmacology
Mechanism of action
Salvinorin A is a selective kappa-opioid receptor agonist with no meaningful activity at serotonin receptors or 50 other molecular targets.[2] Its potency matches dynorphin A — the brain's own κ-opioid activating molecule.[15] Human studies confirm this: the opioid blocker naltrexone completely reverses all effects, while serotonin-blocking drugs have none.[18]
Cannabinoid receptor involvement
Kappa-opioid activation suppresses dopamine release in the brain's reward circuits — driving both the dysphoric quality and the substance's low addictive potential.[5] Salvinorin A does not bind brain cannabinoid receptors,[2] though it reduces gut motility partly through cannabinoid-dependent pathways.[19][20][21][22]
Pharmacokinetics
When smoked or vaporized, salvinorin A reaches peak blood levels within about 2 minutes.[23] Primate brain imaging shows peak uptake at 40 seconds, concentrated in the cerebellum and visual cortex, with a brain half-life of roughly 8 minutes.[24] Oral and sublingual routes are inactive — digestive and salivary enzymes destroy the compound before meaningful absorption occurs.[25][16]
Neuroscience[edit]
Neuroscience
Where it acts
The first human brain imaging study of salvinorin A found that it dissolves the boundaries between brain networks — reducing connectivity within networks and increasing it between them.[10] This pattern resembles what serotonergic psychedelics produce, despite operating through a completely different receptor. Primate imaging confirms the drug concentrates in the cerebellum and visual cortex,[24] consistent with the coordination loss and visual disturbances observed in practice.
Why it matters
Both salvinorin A and psilocybin disrupt the same key brain structure — the claustrum — suggesting network dissolution can arise through more than one pharmacological route.[26] At lower doses, body sensation shifts; at higher doses, external sensory input ceases entirely.[1] This progressive gating fits a model where the brain's predictive filters fail by degrees.
Salvinorin A also suppresses dopamine in the brain's reward circuits.[5] This strips the outside world of motivational significance — explaining the profound detachment from meaning and identity that users describe, which is mechanistically distinct from the ego dissolution produced by serotonergic psychedelics.
How κ-opioid activation in the cerebellum and visual cortex generates elaborate internal imagery remains unknown. Whether kappa-opioid agonism produces any form of neuroplasticity — as serotonergic psychedelics do through distinct pathways — has not been investigated. A twofold sex difference in drug elimination observed in primates[27] has never been studied in humans.
Subjective Effects[edit]
The salvinorin A experience is an abrupt departure from ordinary reality — not a gradual shift but a sudden, involuntary entry into an alien interior space.[1] External sensory input ceases at full doses, replaced by vivid autonomous imagery. The dominant tone is dysphoric and bewildering rather than expansive.
The closest analogies are high-dose ketamine near the anesthetic boundary, or deliriant compounds — though neither captures the combination of preserved internal imagery, complete external disconnection, and predominantly aversive register that defines the experience.[4] Unlike classical psychedelics, the dominant quality is estrangement, not openness.
Effect Grid
Significant dissociation from the external environment. Internal imagery begins — vivid, often bizarre visual scenes that may feel more real than the surrounding room. Altered body ownership and body schema distortion are prominent. The ability to interact with surroundings is substantially reduced. Confusion, time alteration, and language suppression are typical. Cognitive dysphoria — an uncomfortable sense of wrongness or alienation — is frequently reported.
Motor control impairment is significant; users should be seated or lying down before administration. Laughter fits may occur. Spontaneous body sensations and vestibular distortion are common.
A sober sitter is essential. The experience is essentially all peak — there is no gradual come-up. Dysphoric tone predominates. Active effects resolve within 5–20 minutes, with aftereffects lasting 15–60 minutes.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Proprioceptive distortion · Color alteration · Vestibular distortion · Visual morphing · Geometry · Visual breathing · Brightness alteration · Visual drifting · Visual melting · Auditory suppression · Environmental patterning · Touch suppression · Tracers · Visual haze / noise · Visual magnification · After-images · Auditory distortion · Synesthesia · Internal hallucinations · External hallucinations · Object transformations · Object activation · Perspective hallucinations · Visual processing suppression · Auditory hallucinations · Visual flipping · Visual scenery slicing
Geometry · Visual breathing · Brightness alteration · Visual drifting · Visual melting · Auditory suppression · Environmental patterning · Touch suppression · Tracers · Visual haze / noise · Visual magnification · After-images · Auditory distortion · Synesthesia · Internal hallucinations · External hallucinations · Object transformations · Object activation · Perspective hallucinations · Visual processing suppression · Auditory hallucinations · Visual flipping · Visual scenery slicing
Laughter fits · Nausea · Body high · Physical fatigue · Sedation · Bodily heaviness · Bodily lightness · Bodily pressures · Breathing alteration · Heart rate perception changes · Muscle relaxation · Pupil constriction · Spontaneous body sensations · Tingling / electric sensations · Trembling · Vibrations / buzzing · Headache · Muscle tension · Nystagmus (eye wobbles) · Pain suppression · Sexual arousal suppression · Vomiting · Bodily dissociation · Tactile hallucination
Sedation · Bodily heaviness · Bodily lightness · Bodily pressures · Breathing alteration · Heart rate perception changes · Muscle relaxation · Pupil constriction · Spontaneous body sensations · Tingling / electric sensations · Trembling · Vibrations / buzzing · Headache · Muscle tension · Nystagmus (eye wobbles) · Pain suppression · Sexual arousal suppression · Vomiting · Bodily dissociation · Tactile hallucination
Focus suppression · Immersion enhancement · Information processing suppression · Language suppression · Memory suppression · Analysis suppression · Memory fragmentation · Novelty enhancement · Cognitive dysphoria · Thought loops · Humor enhancement · Cognitive fatigue · Conceptual thinking · Introspection enhancement · Memory replays · Multiple thought streams · Pattern recognition suppression · Thought deceleration · Cognitive euphoria · Delirium · Delusions
Language suppression · Memory suppression · Analysis suppression · Memory fragmentation · Novelty enhancement · Cognitive dysphoria · Thought loops · Humor enhancement · Cognitive fatigue · Conceptual thinking · Introspection enhancement · Memory replays · Multiple thought streams · Pattern recognition suppression · Thought deceleration · Cognitive euphoria · Delusions
Simultaneous emotions · Catharsis · Empathy suppression · Euphoria
Social disconnection · Sociability suppression · Automaticity · Disinhibition · Cognitive disconnection · Boundary dissolution · Ego dissolution · Identity alteration
Cognitive disconnection · Boundary dissolution · Ego dissolution · Identity alteration
Time cessation
Cessation · Death-rebirth sequence · Existential realization · Noetic insight · Non-dual awareness · Near-death experience
Non-dual awareness · Near-death experience
Timeline
Near-instantaneous transition from baseline. Effects emerge within seconds of exhalation — a sudden shift in awareness, often described as being 'pulled' out of ordinary reality. There is no gradual build; the onset IS the come-up.
Maximum intensity. At common doses and above: complete dissociation from external reality, vivid internal hallucinations, loss of body schema, motor incapacitation, and frequent amnesia. Dysphoric tone predominates.
Rapid return to baseline. Reorientation to the external environment occurs in stages — awareness of physical surroundings returns before full cognitive coherence. Residual confusion, difficulty articulating the experience, and mild disorientation are common.
Mild residual effects including reflective or confused mental state, physical fatigue, and subtle mood changes. Cognitive processing may feel slightly slowed. Some users report a contemplative or unsettled quality.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- —
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- dynorphin · U50488 · pentazocine
Toxicity
No lethal dose has been established in any species, and no published reports exist of a fatal overdose attributable to salvinorin A alone.safety citation needed The toxic threshold in humans is unknown.[5]
Cardiovascular effects
Controlled studies monitored heart rate and blood pressure during administration.[9][18] All cardiovascular effects were completely blocked by naltrexone, confirming κ-opioid mediation.[18] No serious cardiovascular events occurred in any controlled human study.
Hormonal effects
Salvinorin A produces a brief rise in prolactin beginning about 5 minutes after inhalation, peaking at 15 minutes.[23] This is a characteristic effect of kappa-opioid activation. The clinical significance of this hormonal change with occasional use is not established.
Psychological risks
Kappa-opioid receptor activation inherently produces dysphoria and anxiety — this reflects how the brain's own kappa-opioid stress system works.[5] At high doses, the experience progresses to complete disconnection from external reality, confusion, amnesia, and ego dissolution.[1][4]
The 15–60 second onset means incapacitation arrives before the user can react — creating acute danger from falls, burns from smoking equipment, and uncontrolled movement.[23] Rare case reports document psychotic episodes following use;[28][6] these are uncommon relative to estimated use prevalence,[29] but the association warrants caution in those predisposed to psychosis.
Tolerance and dependence
Tolerance develops through receptor desensitization. Rodent brain imaging found 40–49% fewer available receptors for up to 2.5 hours after the drug clears at higher doses, with no prolonged changes at lower doses.[30] Cross-tolerance is expected with kappa-opioid agonists but not with serotonergic psychedelics (LSD, psilocybin), which work through a completely different receptor system.[18]
Dependence liability is negligible. Salvinorin A suppresses reward circuitry rather than activating it, acting as a punisher rather than a reward in animal studies.[5] Recreational use is characteristically infrequent and curiosity-driven,[12] and no physical withdrawal has been documented.
Drug interactions
No controlled human drug interaction studies have been published.safety citation needed All assessments below are based on mechanistic reasoning.
Opioid antagonists (naltrexone, naloxone): Fully reverse all effects — confirmed in humans.[18] Clinically relevant for emergency management.
Other opioid agonists: Concurrent activation of kappa- and mu-opioid receptors would produce unpredictable additive effects. Not characterized in published literature.
Serotonergic psychedelics (LSD, psilocybin, mescaline): No cross-tolerance exists between these mechanisms.[18] Combining them activates two independent hallucinogenic mechanisms simultaneously, with unpredictable results.
MAO inhibitors: potentiation through monoamine oxidase is not expected — salvinorin A is a terpenoid, not an amine.citation needed Additive CNS effects remain theoretically possible.
SSRIs and SNRIs: Preclinical models suggest SERT blockade may attenuate some effects. Clinical significance is unknown.citation needed
Other medications: Salvinorin A is primarily broken down by esterase enzymes rather than the cytochrome P450 system,[16] reducing the expected risk of interactions with most prescription drugs — though this has not been systematically confirmed.
Contraindications
No controlled studies have evaluated contraindications. The following are based on mechanistic reasoning and case report data.
Psychotic disorders: Individuals with a personal or family history of schizophrenia or psychosis face elevated risk. Case reports associate use with psychotic episodes.[28][6]
Bipolar disorder: The rapid, intense affective swings — from profound dysphoria to confusion and ego dissolution — represent a theoretical risk for mood destabilization.citation needed
Concurrent opioid use: Unpredictable additive pharmacodynamic effects are expected.citation needed
Hazardous physical environments: Near-instantaneous onset (15–60 seconds[23]) and complete incapacitation at higher doses[1] create acute danger near fall hazards, open flames, water, or moving vehicles.
Vehicle operation: Complete motor and cognitive incapacitation during peak effects precludes safe operation of vehicles or machinery.
Harm Reduction[edit]
Forms & Identification
Salvinorin A cannot be detected by standard alkaloid reagent tests (Marquis, Mecke, Simon's).[31][32] Extract concentration labels (5×, 10×, etc.) are unregulated — actual content may differ significantly from stated values. Treat every new batch as an unknown potency and start with the smallest possible amount.
Guidelines
- Test every new batch at the lowest possible dose — potency varies between products and sources
- Use a reclining position — lie down or sit in a supported chair before inhaling
- Always have a sober sitter present who understands the rapid onset and short duration
- Clear the environment of hazards: open flames, sharp objects, hard surfaces within falling distance, bodies of water
- Secure all smoking materials — have the sitter hold the pipe or vaporizer after the dose is inhaled, as motor control will be lost
- Start with plain leaf before trying extracts — move to concentrated extracts only after establishing individual sensitivity
- Allow at least 30 minutes of quiet time after the experience before standing, walking, or leaving the setting
- Do not combine with other psychoactive substances — drug interactions are uncharacterized
Set & Setting
The salvinorin A experience is exceptionally sensitive to environment, and onset is near-instantaneous — there is no time to adjust once the dose is inhaled. A quiet, familiar, physically safe space is essential. Remove sharp objects, open flames, and anything breakable from the immediate area. A reclining position is strongly recommended, as motor control is lost rapidly at active doses.
A sober, trusted sitter is not optional for smoked or vaporized use. The sitter's role is to prevent physical harm — falls, contact with hot surfaces, wandering — and to provide calm, minimal verbal reassurance if distress arises. Physical restraint should only occur if there is immediate danger of serious injury.
Aftercare & integration. The salvinorin A experience is often difficult to articulate, and amnesia for portions is common. Allow time in a quiet setting before attempting to describe or analyze what happened.
Journaling soon after returning to baseline — even fragmented impressions — can help anchor memories before they fade. If the experience produced lasting distress, confusion about reality, or persistent anxiety, professional support from a therapist experienced with altered states is appropriate.
Recovery & Support
Compulsive salvinorin A use is rare — the experience is more commonly abandoned than sought repeatedly.[12] No physical dependence or withdrawal has been documented. If a pattern of repeated use develops despite negative experiences, professional support is warranted.
The Fireside Project (psychedelic peer support line), MAPS integration resources, and local harm reduction organizations can provide guidance and referrals.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Most salvinorin A experiences, even distressing ones, resolve within 20 minutes. Seek emergency help if the person attempts self-harm, becomes physically combative, does not return to baseline awareness within 30 minutes, sustains a fall or burn injury, or shows signs of a psychotic break (persistent delusions, inability to recognize surroundings or people after effects should have resolved).
Immediate steps:
- 1. Ensure physical safety — gently guide the person away from hazards. Do not physically restrain unless there is immediate danger of serious injury.
- 2. Stay calm and speak in short, quiet sentences. Do not attempt to reason with someone in peak dissociation.
- 3. If the person is lying down and unresponsive, place them in the recovery position.
- 4. Call emergency services if the person is injured, if distress does not resolve within 30 minutes, or if psychotic symptoms persist.
What to tell the dispatcher: Name the substance (salvinorin A or Salvia divinorum), approximate amount and form used, time of use, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help.
Reversal agent: Naltrexone and naloxone fully reverse all effects of salvinorin A.[18] Emergency personnel carrying naloxone can administer it if needed.
Legal Status[edit]
Legal status
Salvinorin A and Salvia divinorum are not listed under international drug control treaties, but many individual countries and states have enacted bans or restrictions.[32]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States (federal) | Unscheduled | DEA lists as "Drug and Chemical of Concern"; no federal scheduling[33] |
| United States (states) | Varies | Approximately 27 states have enacted bans or restrictions |
| Australia | Schedule 9 (Prohibited) | Banned since June 1, 2002; first country to prohibit[33] |
| United Kingdom | Prohibited | Covered under Psychoactive Substances Act 2016[33] |
| Canada | Schedule IV (CDSA) | Sale and manufacture prohibited since approximately 2015[33] |
| Germany | Appendix I (BtMG) | Controlled under Narcotics Act since March 1, 2008[33] |
| Sweden | Prohibited | Illegal since April 1, 2006 |
| France | Controlled | Listed as poisonous substance since August 2010; illegal for human consumption |
| Italy | Prohibited | Prohibited since January 2005 |
| Netherlands | Unscheduled | No scheduling as of available data |
| New Zealand | Controlled | Psychoactive Substances Act 2014 |
Legal status changes frequently. This information reflects available data and is not legal advice — verify current laws in your jurisdiction before acting on this information.
references
- [1] ^abcdefghMaqueda AE, Valle M, Addy PH, Antonijoan RM, Puntes M, Coimbra J, Ballester MR, Garrido M, González M, Claramunt J, Barker S, Johnson MW, Griffiths RR, Riba J (2015) Salvinorin-A Induces Intense Dissociative Effects, Blocking External Sensory Perception and Modulating Interoception and Sense of Body Ownership in Humans. — The international journal of neuropsychopharmacology doi:10.1093/ijnp/pyv065
- [2]
- [3] ^abcdCasselman I, Nock CJ, Wohlmuth H, Weatherby RP, Heinrich M (2014) From local to global-fifty years of research on Salvia divinorum. — Journal of ethnopharmacology doi:10.1016/j.jep.2013.11.032
- [4] ^abcdMacLean KA, Johnson MW, Reissig CJ, Prisinzano TE, Griffiths RR (2013) Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects. — Psychopharmacology doi:10.1007/s00213-012-2912-9
- [5]
- [6] ^abcEl-Khoury J, Sahakian N (2015) The Association of Salvia divinorum and Psychotic Disorders: A Review of the Literature and Case Series. — Journal of psychoactive drugs doi:10.1080/02791072.2015.1073815